STAR Stock Overview
Develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
Strides Pharma Science Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,503.65 |
| 52 Week High | ₹1,675.00 |
| 52 Week Low | ₹482.00 |
| Beta | 0.73 |
| 11 Month Change | -3.22% |
| 3 Month Change | 15.31% |
| 1 Year Change | 203.61% |
| 33 Year Change | 197.63% |
| 5 Year Change | 287.14% |
| Change since IPO | 67.88% |
Recent News & Updates
Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors
Nov 01
Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge
Oct 21Recent updates
Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors
Nov 01Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge
Oct 21After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar
Aug 14Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)
Apr 04Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story
Dec 23We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 02Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50
Jul 28Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)
Apr 13Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?
Mar 04These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?
Jan 26The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It
Jan 11
Shareholder Returns
| STAR | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 6.2% | -0.2% | 0.3% |
| 1Y | 203.6% | 40.5% | 27.3% |
Return vs Industry: STAR exceeded the Indian Pharmaceuticals industry which returned 40.5% over the past year.
Return vs Market: STAR exceeded the Indian Market which returned 27.3% over the past year.
Price Volatility
| STAR volatility | |
|---|---|
| STAR Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: STAR has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: STAR's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 3,065 | Badree Komandur | www.strides.com |
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams.
Strides Pharma Science Limited Fundamentals Summary
| STAR fundamental statistics | |
|---|---|
| Market cap | ₹128.02b |
| Earnings (TTM) | ₹1.77b |
| Revenue (TTM) | ₹44.10b |
78.1x
P/E Ratio3.1x
P/S RatioIs STAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STAR income statement (TTM) | |
|---|---|
| Revenue | ₹44.10b |
| Cost of Revenue | ₹19.25b |
| Gross Profit | ₹24.85b |
| Other Expenses | ₹23.08b |
| Earnings | ₹1.77b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 19.25 |
| Gross Margin | 56.35% |
| Net Profit Margin | 4.01% |
| Debt/Equity Ratio | 100.0% |
How did STAR perform over the long term?
See historical performance and comparison